Cristian Fiori1, Francesco Porpiglia1, Enrico Checcucci2,3,4, Stefano De Luca1, Federico Piramide1, Diletta Garrou5,1, Alessandra Mosca6, Andrea Galla7, Gaetano Belli7, Filippo Russo8, Pasquale Rescigno9, Carlo Poti10, Daniele Amparore1, Paolo Verri1, Gabriele Volpi1, Matteo Manfredi1. 1. Department of Oncology, Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. 2. Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, km 3,95, 10060, Candiolo, Turin, Italy. checcu.e@hotmail.it. 3. Uro-Technology and SoMe Working Group of the Young Academic Urologists (YAU) Working Party of the European Association of Urology (EAU), Arnhem, The Netherlands. checcu.e@hotmail.it. 4. Department of Oncology, Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. checcu.e@hotmail.it. 5. Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, km 3,95, 10060, Candiolo, Turin, Italy. 6. Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. 7. Division of Radiation Therapy, Candiolo Cancer Institute, Candiolo, Turin, Italy. 8. Department of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. 9. Interdisciplinary Group for Translational Research and Clinical Trials (GIRT-Uro), Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy. 10. Department of Nuclear Medicine, Azienda USL Della Valle d'Aosta, Aosta, Italy.
Abstract
PURPOSE: To assess the use of the new Focal-One® HIFU platform in salvage setting to evaluate the occurrence of postoperative complications. METHODS: Patients who underwent salvage HIFU (sHIFU) with Focal-One® platform were enrolled prospectively (Candiolo cancer institute-FPO IRCCS; registry number: 258/2018). Perioperative and postoperative outcomes (in terms of oncological and functional ones) were recorded during the first year of follow-up. In particular postoperative complications were classified according to Clavien-Dindo system. RESULTS: 20 patients were enrolled. No grade 3 complications were recorded. Referring to grade 2 complications, eight patients reported urgency after 3 months of follow-up, and in 4 cases, a low urinary tract infection occurred. Evaluating the impact of sHIFU on patients' sexual potency, micturition and quality of life, no significant deterioration was recorded during the follow-up as proven using the ANOVA analysis for repeated measurements. Only two patient had a biochemical failure after 12 months of follow-up. CONCLUSIONS: The real-time intraoperative guidance with Focal-One® platform, allows a continuous monitoring and tailoring of the treatment, with a minimization of the adverse events even in a salvage setting.
PURPOSE: To assess the use of the new Focal-One® HIFU platform in salvage setting to evaluate the occurrence of postoperative complications. METHODS: Patients who underwent salvage HIFU (sHIFU) with Focal-One® platform were enrolled prospectively (Candiolo cancer institute-FPO IRCCS; registry number: 258/2018). Perioperative and postoperative outcomes (in terms of oncological and functional ones) were recorded during the first year of follow-up. In particular postoperative complications were classified according to Clavien-Dindo system. RESULTS: 20 patients were enrolled. No grade 3 complications were recorded. Referring to grade 2 complications, eight patients reported urgency after 3 months of follow-up, and in 4 cases, a low urinary tract infection occurred. Evaluating the impact of sHIFU on patients' sexual potency, micturition and quality of life, no significant deterioration was recorded during the follow-up as proven using the ANOVA analysis for repeated measurements. Only two patient had a biochemical failure after 12 months of follow-up. CONCLUSIONS: The real-time intraoperative guidance with Focal-One® platform, allows a continuous monitoring and tailoring of the treatment, with a minimization of the adverse events even in a salvage setting.
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Kerri Beckmann; Hans Garmo; Jan Adolfsson; Cecilia Bosco; Eva Johansson; David Robinson; Lars Holmberg; Par Stattin; Mieke Van Hemelrijck Journal: Eur Urol Date: 2018-11-26 Impact factor: 20.096
Authors: Wei Liu; Katherine Zukotynski; Louise Emmett; Hans T Chung; Peter Chung; Robert Wolfson; Irina Rachinsky; Anil Kapoor; Ur Metser; Andrew Loblaw; Gerard Morton; Tracy Sexton; Michael Lock; Joelle Helou; Alejandro Berlin; Colm Boylan; Susan Archer; Gregory R Pond; Glenn Bauman Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-12 Impact factor: 7.038
Authors: Abi Kanthabalan; Max Peters; Marco Van Vulpen; Neil McCartan; Richard Graham Hindley; Amr Emara; Caroline M Moore; Manit Arya; Mark Emberton; Hashim Uddin Ahmed Journal: BJU Int Date: 2017-04-03 Impact factor: 5.588
Authors: Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke Journal: Eur Urol Date: 2015-09-08 Impact factor: 20.096